In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 361 to 370 of 388

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]	Technology appraisal guidance	2 December 2026
Total hip arthroplasty using the superpath approach for osteoarthritis	Interventional procedures guidance	TBC
Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over [ID6557]	Technology appraisal guidance	TBC
Transvenous embolisation for spontaneous intracranial hypotension caused by a cerebrospinal fluid–venous fistula	Interventional procedures guidance	TBC
Trastuzumab deruxtecan for treating HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma after trastuzumab-based treatment (review of TA879) [ID6680]	Technology appraisal guidance	TBC
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]	Technology appraisal guidance	7 May 2026
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]	Technology appraisal guidance	TBC
Trilaciclib for preventing myelosuppression caused by chemotherapy for extensive-stage small-cell lung cancer [ID6651]	Technology appraisal guidance	TBC
Unilateral and staged bilateral MRI-guided focused ultrasound thalamotomy for medication-refractory essential tremor	Interventional procedures guidance	17 December 2026
Upadacitinib for treating giant cell arteritis [ID6299]	Technology appraisal guidance	TBC

Results per page

10
25
50
All